Sandoz Unveils $400m+ Investment In Slovenian Biosimilars Plant
Lendava Biologics Facility Is Expected To Become Fully Operational By 2026
Spurred on by “increasing global demand for biosimilar medicines,” Sandoz has revealed plans to invest at least $400m in building a new biologics production plant in Slovenia.
You may also be interested in...
Sandoz has filled a gap in its biosimilars pipeline by in-licensing Samsung Bioepis’ SB17 ustekinumab biosimilar to Stelara, for commercialization in multiple global markets.
On the back of recently-announced initiatives and alliances to bolster its biosimilars business ahead of its upcoming spinoff from parent company Novartis, Sandoz has revealed a further investment of around $90m to construct a technical development center in Slovenia.
Double-digit growth in the Europe region and in its biosimilars business helped to push up sales for Sandoz in the second quarter and first half of 2023.